Galen Femring approved
Executive Summary
Galen Femring (estradiol acetate) to launch in U.S. market in June following FDA approval March 20. The hormone therapy is second approved since FDA halted the Women's Health Initiative study in July 2002. Femring labeling follows Wyeth's template, including "black box" warning of increased incidence cardiovascular disease and breast cancer with long-term use (1"The Pink Sheet" Jan. 13, p. 21). Femring will be available in two doses, .05 mg/day or .1 mg/day, with each ring delivering estrogen over a three-month period...
You may also be interested in...
Galen Femring Includes HRT Class Labeling; Launch In June
Labeling for Galen's vaginal hormone therapy Femring follows the template established for Wyeth's Premarin family to incorporate the findings from NIH's Women's Health Initiative study
Hormone Therapy Class Labeling Uses Wyeth Template; Appeals Due By March
Sponsors of hormone replacement therapies have two months to pull together data to justify exemptions to FDA's proposed class labeling incorporating risk information from the Women's Health Initiative
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.